Literature DB >> 8409405

Macrophage inflammatory protein-1 alpha rapidly modulates its receptors and inhibits the anti-CD3 mAb-mediated proliferation of T lymphocytes.

Z Zhou1, Y J Kim, K Pollok, J Hurtado, J K Lee, H E Broxmeyer, B S Kwon.   

Abstract

Macrophage inflammatory protein-1 alpha (MIP-1 alpha) is a member of the intercrine/chemokine family which consists of basic, heparin-binding, small molecular weight proteins. We have previously shown that a T cell line, CTLL-R8, carried high-affinity receptors for MIP-1 alpha and the proliferation of CTLL-R8 cells was inhibited by murine recombinant (mr) MIP-1 alpha. We extended our previous studies to murine resting splenic T lymphocytes to determine whether the inhibition of T cell proliferation is a general property of MIP-1 alpha. The resting splenic T cells carried approximately 680 high-affinity binding sites for mrMIP-1 alpha; more than 90% of the primary T cells carried MIP-1 alpha receptors. When the T cells were stimulated with immobilized anti-CD3 mAb in the presence of accessory cells, the MIP-1 alpha binding was reduced. The lowest binding was obtained 2 h after anti-CD3 mAb stimulation due to the internalization of MIP-1 alpha receptors. mrMIP-1 alpha inhibited the anti-CD3 mAb-mediated proliferation of murine splenic T lymphocytes. The maximum inhibition was obtained when mrMIP-1 alpha was added 30 min before anti-CD3 mAb stimulation. Slight inhibition of T cell proliferation was observed when mrMIP-1 alpha was added at the same time as anti-CD3 mAb stimulation. These results indicate that T lymphocytes are regulated negatively by MIP-1 alpha, which occurs when the T cells are exposed to MIP-1 alpha before activation. The negative effect of MIP-1 alpha seems to be mediated in part by the inhibition of IL-2 production, for there was a reduction in both the IL-2 mRNA levels and the IL-2 activity in supernatants from T cells preincubated with MIP-1 alpha before anti-CD3 mAb stimulation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8409405

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

Review 1.  Chemokines: understanding their role in T-lymphocyte biology.

Authors:  S G Ward; J Westwick
Journal:  Biochem J       Date:  1998-08-01       Impact factor: 3.857

2.  Correlation between plasma levels of cytokines and HIV-1 RNA copy number in HIV-infected patients.

Authors:  G Hittinger; C Poggi; E Delbeke; N Profizi; A Lafeuillade
Journal:  Infection       Date:  1998 Mar-Apr       Impact factor: 3.553

3.  The role of cytokines, adhesion molecules, and chemokines in interleukin-2-induced lymphocytic infiltration in C57BL/6 mice.

Authors:  J A Anderson; A B Lentsch; D J Hadjiminas; F N Miller; A W Martin; K Nakagawa; M J Edwards
Journal:  J Clin Invest       Date:  1996-04-15       Impact factor: 14.808

4.  Interplay between the heterotrimeric G-protein subunits Galphaq and Galphai2 sets the threshold for chemotaxis and TCR activation.

Authors:  Jacob Ngai; Marit Inngjerdingen; Torunn Berge; Kjetil Taskén
Journal:  BMC Immunol       Date:  2009-05-08       Impact factor: 3.615

5.  Human G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis.

Authors:  B A Zabel; W W Agace; J J Campbell; H M Heath; D Parent; A I Roberts; E C Ebert; N Kassam; S Qin; M Zovko; G J LaRosa; L L Yang; D Soler; E C Butcher; P D Ponath; C M Parker; D P Andrew
Journal:  J Exp Med       Date:  1999-11-01       Impact factor: 14.307

6.  Senescent Vascular Smooth Muscle Cells Drive Inflammation Through an Interleukin-1α-Dependent Senescence-Associated Secretory Phenotype.

Authors:  Sarah E Gardner; Melanie Humphry; Martin R Bennett; Murray C H Clarke
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-07-02       Impact factor: 8.311

7.  Human Mig chemokine: biochemical and functional characterization.

Authors:  F Liao; R L Rabin; J R Yannelli; L G Koniaris; P Vanguri; J M Farber
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.